Study of Neoantigen mRNA Vaccines in Patients With Resectable Pancreatic Cancer
Conditions: Pancreatic Cancer Interventions: Procedure: Surgery; Drug: Camrelizumab; Biological: SJ-Neo006; Drug: Gemcitabine+Abraxane Sponsors: Jinling Hospital, China; Jiangsu Synthgene Biotechnology Co.Ltd. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Abraxane | Biotechnology | Cancer | Cancer & Oncology | Cancer Vaccines | China Health | Hospitals | Pancreas | Pancreatic Cancer | Research | Study | Vaccines